A new analysis by Cedar Gate Technologies, an IQVIA business (Cedar Gate), found a 13% decline in bariatric surgery volume over the past year, alongside a 67% increase in total members taking glucagon-like peptide-1 (GLP-1) medications over the past two years, indicating a notable shift toward nonsurgical weight loss treatments. The analysis also examined the total cost of bariatric surgery compared to GLP-1 prescriptions. In 2024, the average cost of bariatric surgery was $24,215, a 9.62% increase over the prior year. By comparison, the average annual cost per patient for GLP-1 prescriptions was approximately $5,200, up 8.33% from 2023.
Read the full article: GLP-1 Usage Increases 67% While Bariatric Surgeries Decline //
Source: https://www.globenewswire.com/news-release/2026/02/18/3240222/0/en/GLP-1-Usage-Increases-67-While-Bariatric-Surgeries-Decline-but-Long-Term-Benefits-Remain-Unclear.html?_gl=1*12sgokf*_up*MQ..*_ga*MTA1Mjg4NDg2OC4xNzcxNDIzNjUx*_ga_B6167QB2TF*czE3NzE0MjM2NTEkbzEkZzAkdDE3NzE0MjM2NTEkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzE0MjM2NTEkbzEkZzAkdDE3NzE0MjM2NTEkajYwJGwwJGgw